Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Controversial point here but in my view the most accurate scoop over the last 18months was actually by Sticky when he managed to get the CE-mark delay information. Given the relative ease of getting this it’s almost certain that the GAD output numbers are known to a large cohort. I sincerely hope that this and other intelligence re: EU contracts, HUA, Medusa capacity come good…
Who was it that suggested making a movie of the Avacta saga? Our main man missing in action following a trip to Avacta towers, gagged with an AffiDx between the teeth by Sir Al. To be released “shortly”. Poor soul could be there for years.
The CEO did say that he would update on uk capacity as soon as he could do so. Since then we know that Omega won’t be manufacturing the Avacta test.
I had expected an update by now to confirm the position and allow us to move on with certainty. I am torn between (a) the CEO doesn’t want to update the market on bad news, perhaps until that RoW capacity is secured (b) discussions remain ongoing in relation to GAD capacity
At this stage I feel like there is limited downside to full transparency on LFT capacity. The market seems to have (rightly or wrongly) assumed the worst.
I am not patient enough for jigsaw puzzles…however if the 20 day turnaround is calendar (not working) days then does this not take us right up to August 16th? So an application submitted yesterday could have approval on that date?
No, I would want to verify the claims . In the ODX presentation their CEO mentioned something along the lines that, when securing deals for the Visitect test, customers were looking to perform studies to prove superiority to their current procured tests. If I recall the tone it suggested a more lengthy process to secure deals. I imagine this is where Avacta is at right now.
I am looking forward to confirmation of the test odx will make. Best case it’s Avacta, worst case it gets the sovereign debate over and done with and we can look forward to EU/RoW.
I am hoping that the UK/ further validation study is being held back to put a bit of fuel under the SP in either eventuality.
Would love this to be the case. Optimistic case:
- CEO has specifically mentioned access to government machines
- Given Porton Down issue has been known about since at least start of the year you would expect there to be a clear plan to overcome this
But…
- ODX CEO stated that the selected test would be one that is already in scale production and already home use approved
So unless we go back to the NDA thesis (eg we get a bumper RNS that passes 3a, approves home use and contract signed all in one go) it looks like the candidates are Healgen or Orient Gene…
https://twitter.com/visionaryprop/status/1404786382720094211?s=21
Thanks AgentB. I am curious about the word “delay” and whether this means Avacta strategy is to skip straight to the new private protocol (which uses real world samples) OR whether they have a plan to address the underlying PD issue. By the time we find out it’s probably academic anyway as the private protocol will have kicked in.
Looking at the recent tweets (and letters to MPs) on Porton Down I hear 3 versions of why the uk tests are struggling- frozen samples not suitable for S protein- use of pigs mucin- incorrect use of suppliers bufferThere have been some well researched posts on the above, does anyone have clarity on which one has/is the stumbling block?
Random thought - Does this now allow the Abingdon TT to officially complete? A direct Avacta:Abingdon relationship certainly makes more contractual sense than a three-way Avacta:GAD:Abingdon. Same may be said for any dealings with Medusa?
Whats clear is that home use approval is pivotal. Mologic targeting the home use US market and have adjusted their product to suit, Omega going to produce a test that has home use approval…once we get the home use approval it will really transform the proposition for global sales.
If Avacta/Medusa have managed to somehow get home use approval just-in-time to be considered for the UK government let’s see.
Whatever market now would be a great time to announce.
I presume the only candidates would be Acon Flowflex (which appears to have home use approval already), or an EUA extension to either Innova or Orient Gene. Interesting to hear how Mologic/Omega had to tweak their buffer design to qualify for home use application; looking at the format Avacta test does seem to have a more intuitive buffer design from the outset.
I do love a conspiracy (clearly much prefer real news flow and a better SP) and agree this is very plausible. Lack of any presence of DSWilson in any investor events, Board member stepping down earlier in the year retaining focus on therapeutics only (am going to take another look at that RNS), CEO stressing the attention the company has received as well as the staff independence between therapeutics and diagnostics.